With FSC treatment, much of the impacts of anemia can be curbed. Stem Cell Therapy has been proven to treat primary and secondary Anemia – including aplastic and hereditary anemia.

Unlike pharmacological therapy which mainly focuses on blood transfusions to address the RBC deficiency and stimulating the patient’s bone marrow, stem cell therapy transplants erythropoietic cells, or erythrocyte precursors, to increase the number of cells responsible for hematopoies. This brings up the levels of hemoglobin grow, which subsequently leads to significant improvement in patient’s overall quality of life.

Fetal Stem Cell treatment has been particularly successful in severe aplastic anemic cases. High hemoglobin levels were observed in all cases for many years after one or two courses of FSC transplantation. The patients haven’t had to undergo regular treatments after this treatment.

Patients suffering from sickle cell anemia have been benefitted with stem cell therapy, as it has reduced the frequency of crisis for them, soothing their course and decrease the need for blood transfusions.

In case of hereditary anemia, stem cell therapy has also been effective. However, treatment effects decrease with time and there will be a need for subsequent courses of treatments.